\BOOKMARK [0][-]{chapter.1}{Introduction}{}% 1
\BOOKMARK [1][-]{section.1.1}{Cancer Research in the Post-Genomic Era}{chapter.1}% 2
\BOOKMARK [2][-]{subsection.1.1.1}{Cancer as a Global Health Concern}{section.1.1}% 3
\BOOKMARK [3][-]{subsubsection.1.1.1.1}{Genetics and Molecular Biology in Cancers}{subsection.1.1.1}% 4
\BOOKMARK [2][-]{subsection.1.1.2}{The Human Genome Revolution}{section.1.1}% 5
\BOOKMARK [3][-]{subsubsection.1.1.2.1}{The First Human Genome Sequence}{subsection.1.1.2}% 6
\BOOKMARK [3][-]{subsubsection.1.1.2.2}{Impact of Genomics}{subsection.1.1.2}% 7
\BOOKMARK [2][-]{subsection.1.1.3}{Technologies to Enable Genetics Research}{section.1.1}% 8
\BOOKMARK [3][-]{subsubsection.1.1.3.1}{DNA Sequencing and Genotyping Technologies}{subsection.1.1.3}% 9
\BOOKMARK [3][-]{subsubsection.1.1.3.2}{Microarrays and Quantitative Technologies}{subsection.1.1.3}% 10
\BOOKMARK [3][-]{subsubsection.1.1.3.3}{Massively Parallel ``Next Generation'' Sequencing}{subsection.1.1.3}% 11
\BOOKMARK [4][-]{subsubsubsection.1.1.3.3.1}{Molecular Profiling with Genomics Technology}{subsubsection.1.1.3.3}% 12
\BOOKMARK [4][-]{subsubsubsection.1.1.3.3.2}{Established Sequencing Technologies}{subsubsection.1.1.3.3}% 13
\BOOKMARK [4][-]{subsubsubsection.1.1.3.3.3}{Emerging Sequencing Technologies}{subsubsection.1.1.3.3}% 14
\BOOKMARK [3][-]{subsubsection.1.1.3.4}{Bioinformatics as Interdisciplinary Genomic Analysis}{subsection.1.1.3}% 15
\BOOKMARK [2][-]{subsection.1.1.4}{Follow-up Large-Scale Genomics Projects}{section.1.1}% 16
\BOOKMARK [2][-]{subsection.1.1.5}{Cancer Genomes}{section.1.1}% 17
\BOOKMARK [3][-]{subsubsection.1.1.5.1}{The Cancer Genome Atlas Project}{subsection.1.1.5}% 18
\BOOKMARK [3][-]{subsubsection.1.1.5.2}{The International Cancer Genome Consortium}{subsection.1.1.5}% 19
\BOOKMARK [4][-]{subsubsubsection.1.1.5.2.1}{Findings from Cancer Genomes}{subsubsection.1.1.5.2}% 20
\BOOKMARK [4][-]{subsubsubsection.1.1.5.2.2}{Genomic Comparisons Across Cancer Tissues}{subsubsection.1.1.5.2}% 21
\BOOKMARK [4][-]{subsubsubsection.1.1.5.2.3}{Cancer Genomic Data Resouces}{subsubsection.1.1.5.2}% 22
\BOOKMARK [2][-]{subsection.1.1.6}{Genomic Cancer Medicine}{section.1.1}% 23
\BOOKMARK [3][-]{subsubsection.1.1.6.1}{Cancer Genes and Driver Mutations}{subsection.1.1.6}% 24
\BOOKMARK [3][-]{subsubsection.1.1.6.2}{Personalised or Precision Cancer Medicine}{subsection.1.1.6}% 25
\BOOKMARK [4][-]{subsubsubsection.1.1.6.2.1}{Molecular Diagnostics and Pan-Cancer Medicine}{subsubsection.1.1.6.2}% 26
\BOOKMARK [3][-]{subsubsection.1.1.6.3}{Targeted Therapeutics and Pharmacogenomics}{subsection.1.1.6}% 27
\BOOKMARK [4][-]{subsubsubsection.1.1.6.3.1}{Targeting Oncogenic Driver Mutations}{subsubsection.1.1.6.3}% 28
\BOOKMARK [3][-]{subsubsection.1.1.6.4}{Systems and Network Biology}{subsection.1.1.6}% 29
\BOOKMARK [4][-]{subsubsubsection.1.1.6.4.1}{ Network Medicine, and Polypharmacology}{subsubsection.1.1.6.4}% 30
\BOOKMARK [1][-]{section.1.2}{A Synthetic Lethal Approach to Cancer Medicine}{chapter.1}% 31
\BOOKMARK [2][-]{subsection.1.2.1}{Synthetic Lethal Genetic Interactions}{section.1.2}% 32
\BOOKMARK [2][-]{subsection.1.2.2}{Synthetic Lethal Concepts in Genetics}{section.1.2}% 33
\BOOKMARK [2][-]{subsection.1.2.3}{Studies of Synthetic Lethality}{section.1.2}% 34
\BOOKMARK [3][-]{subsubsection.1.2.3.1}{Synthetic Lethal Pathways and Networks}{subsection.1.2.3}% 35
\BOOKMARK [4][-]{subsubsubsection.1.2.3.1.1}{Evolution of Synthetic Lethality}{subsubsection.1.2.3.1}% 36
\BOOKMARK [2][-]{subsection.1.2.4}{Synthetic Lethal Concepts in Cancer}{section.1.2}% 37
\BOOKMARK [2][-]{subsection.1.2.5}{Clinical Impact of Synthetic Lethality in Cancer}{section.1.2}% 38
\BOOKMARK [2][-]{subsection.1.2.6}{High-throughput Screening for Synthetic Lethality}{section.1.2}% 39
\BOOKMARK [3][-]{subsubsection.1.2.6.1}{Synthetic Lethal Screens}{subsection.1.2.6}% 40
\BOOKMARK [2][-]{subsection.1.2.7}{Computational Prediction of Synthetic Lethality}{section.1.2}% 41
\BOOKMARK [3][-]{subsubsection.1.2.7.1}{Bioinformatics Approaches to Genetic Interactions}{subsection.1.2.7}% 42
\BOOKMARK [3][-]{subsubsection.1.2.7.2}{Comparative Genomics}{subsection.1.2.7}% 43
\BOOKMARK [3][-]{subsubsection.1.2.7.3}{Analysis and Modelling of Protein Data}{subsection.1.2.7}% 44
\BOOKMARK [3][-]{subsubsection.1.2.7.4}{Differential Gene Expression}{subsection.1.2.7}% 45
\BOOKMARK [3][-]{subsubsection.1.2.7.5}{Data Mining and Machine Learning}{subsection.1.2.7}% 46
\BOOKMARK [3][-]{subsubsection.1.2.7.6}{Bimodality}{subsection.1.2.7}% 47
\BOOKMARK [3][-]{subsubsection.1.2.7.7}{Rationale for Further Development}{subsection.1.2.7}% 48
\BOOKMARK [1][-]{section.1.3}{E-cadherin as a Synthetic Lethal Target}{chapter.1}% 49
\BOOKMARK [2][-]{subsection.1.3.1}{The CDH1 gene and it's Biological Functions}{section.1.3}% 50
\BOOKMARK [3][-]{subsubsection.1.3.1.1}{Cytoskeleton}{subsection.1.3.1}% 51
\BOOKMARK [3][-]{subsubsection.1.3.1.2}{Extracellular and Tumour Micro-Environment}{subsection.1.3.1}% 52
\BOOKMARK [3][-]{subsubsection.1.3.1.3}{Cell-Cell Adhesion and Signalling}{subsection.1.3.1}% 53
\BOOKMARK [2][-]{subsection.1.3.2}{CDH1 as a Tumour \(and Invasion\) Suppressor}{section.1.3}% 54
\BOOKMARK [3][-]{subsubsection.1.3.2.1}{Breast Cancers and Invasion}{subsection.1.3.2}% 55
\BOOKMARK [2][-]{subsection.1.3.3}{Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer}{section.1.3}% 56
\BOOKMARK [2][-]{subsection.1.3.4}{Somatic Mutations}{section.1.3}% 57
\BOOKMARK [3][-]{subsubsection.1.3.4.1}{Mutation Rate}{subsection.1.3.4}% 58
\BOOKMARK [3][-]{subsubsection.1.3.4.2}{Co-occuring Mutations}{subsection.1.3.4}% 59
\BOOKMARK [2][-]{subsection.1.3.5}{Models of CDH1 loss in cell lines}{section.1.3}% 60
\BOOKMARK [1][-]{section.1.4}{Summary and Research Direction of Thesis}{chapter.1}% 61
\BOOKMARK [0][-]{chapter.2}{Methods and Resources}{}% 62
\BOOKMARK [1][-]{section.2.1}{Bioinformatics Resources for Genomics Research}{chapter.2}% 63
\BOOKMARK [2][-]{subsection.2.1.1}{Public Data and Software Packages}{section.2.1}% 64
\BOOKMARK [3][-]{subsubsection.2.1.1.1}{Cancer Genome Atlas Data}{subsection.2.1.1}% 65
\BOOKMARK [3][-]{subsubsection.2.1.1.2}{Reactome and Annotation Data}{subsection.2.1.1}% 66
\BOOKMARK [1][-]{section.2.2}{Data Handling}{chapter.2}% 67
\BOOKMARK [2][-]{subsection.2.2.1}{Normalisation}{section.2.2}% 68
\BOOKMARK [2][-]{subsection.2.2.2}{Sample Triage}{section.2.2}% 69
\BOOKMARK [2][-]{subsection.2.2.3}{Metagenes and the Singular Value Decomposition}{section.2.2}% 70
\BOOKMARK [3][-]{subsubsection.2.2.3.1}{Candidate Triage and Integration with Screen Data}{subsection.2.2.3}% 71
\BOOKMARK [1][-]{section.2.3}{Techniques}{chapter.2}% 72
\BOOKMARK [2][-]{subsection.2.3.1}{Statistical Procedures and Tests}{section.2.3}% 73
\BOOKMARK [2][-]{subsection.2.3.2}{Gene Set Over-representation Analysis}{section.2.3}% 74
\BOOKMARK [2][-]{subsection.2.3.3}{Clustering}{section.2.3}% 75
\BOOKMARK [2][-]{subsection.2.3.4}{Heatmap}{section.2.3}% 76
\BOOKMARK [2][-]{subsection.2.3.5}{Modeling and Simulations}{section.2.3}% 77
\BOOKMARK [3][-]{subsubsection.2.3.5.1}{Receiver Operating Characteristic \(Performance\)}{subsection.2.3.5}% 78
\BOOKMARK [2][-]{subsection.2.3.6}{Resampling Analysis}{section.2.3}% 79
\BOOKMARK [1][-]{section.2.4}{Pathway Structure Methods}{chapter.2}% 80
\BOOKMARK [2][-]{subsection.2.4.1}{Network and Graph Analysis}{section.2.4}% 81
\BOOKMARK [2][-]{subsection.2.4.2}{Sourcing Graph Structure Data}{section.2.4}% 82
\BOOKMARK [2][-]{subsection.2.4.3}{Constructing Pathway Subgraphs}{section.2.4}% 83
\BOOKMARK [2][-]{subsection.2.4.4}{Network Analysis Metrics}{section.2.4}% 84
\BOOKMARK [1][-]{section.2.5}{Implementation}{chapter.2}% 85
\BOOKMARK [2][-]{subsection.2.5.1}{Computational Resources and Linux Utilities}{section.2.5}% 86
\BOOKMARK [2][-]{subsection.2.5.2}{R Language and Packages}{section.2.5}% 87
\BOOKMARK [2][-]{subsection.2.5.3}{High Performance and Parallel Computing}{section.2.5}% 88
\BOOKMARK [0][-]{chapter.3}{Methods Developed During Thesis}{}% 89
\BOOKMARK [1][-]{section.3.1}{A Synthetic Lethal Detection Methodology}{chapter.3}% 90
\BOOKMARK [1][-]{section.3.2}{Synthetic Lethal Simulation and Modelling}{chapter.3}% 91
\BOOKMARK [2][-]{subsection.3.2.1}{A Model of Synthetic Lethality in Expression Data}{section.3.2}% 92
\BOOKMARK [2][-]{subsection.3.2.2}{Simulation Procedure}{section.3.2}% 93
\BOOKMARK [1][-]{section.3.3}{Detecting Simulated Synthetic Lethal Partners}{chapter.3}% 94
\BOOKMARK [2][-]{subsection.3.3.1}{Binomial Simulation of Synthetic lethality}{section.3.3}% 95
\BOOKMARK [2][-]{subsection.3.3.2}{Multivariate Normal Simulation of Synthetic lethality}{section.3.3}% 96
\BOOKMARK [3][-]{subsubsection.3.3.2.1}{Multivariate Normal Simulation with Correlated Genes}{subsection.3.3.2}% 97
\BOOKMARK [3][-]{subsubsection.3.3.2.2}{Specificity with Query-Correlated Pathways}{subsection.3.3.2}% 98
\BOOKMARK [4][-]{subsubsubsection.3.3.2.2.1}{Importance of Directional Testing}{subsubsection.3.3.2.2}% 99
\BOOKMARK [1][-]{section.3.4}{Graph Structure Methods}{chapter.3}% 100
\BOOKMARK [2][-]{subsection.3.4.1}{Upstream and Downstream Gene Detection}{section.3.4}% 101
\BOOKMARK [3][-]{subsubsection.3.4.1.1}{Permutation Analysis for Statistical Significance}{subsection.3.4.1}% 102
\BOOKMARK [3][-]{subsubsection.3.4.1.2}{Ranking Based on Biological Context}{subsection.3.4.1}% 103
\BOOKMARK [2][-]{subsection.3.4.2}{Simulating Gene Expression from Graph Structures}{section.3.4}% 104
\BOOKMARK [1][-]{section.3.5}{Customised Functions and Packages Developed}{chapter.3}% 105
\BOOKMARK [2][-]{subsection.3.5.1}{Synthetic Lethal Interaction Prediction Tool}{section.3.5}% 106
\BOOKMARK [2][-]{subsection.3.5.2}{Data Visualisation}{section.3.5}% 107
\BOOKMARK [2][-]{subsection.3.5.3}{Extensions to the iGraph Package}{section.3.5}% 108
\BOOKMARK [3][-]{subsubsection.3.5.3.1}{Sampling Simulated Data from Graph Structures}{subsection.3.5.3}% 109
\BOOKMARK [3][-]{subsubsection.3.5.3.2}{Plotting Directed Graph Structures}{subsection.3.5.3}% 110
\BOOKMARK [3][-]{subsubsection.3.5.3.3}{Computing Information Centrality}{subsection.3.5.3}% 111
\BOOKMARK [3][-]{subsubsection.3.5.3.4}{Testing Pathway Structure with Permutation Testing}{subsection.3.5.3}% 112
\BOOKMARK [3][-]{subsubsection.3.5.3.5}{Metapackage to Install iGraph Functions}{subsection.3.5.3}% 113
\BOOKMARK [0][-]{chapter.4}{Synthetic Lethal Analysis of Gene Expression Data}{}% 114
\BOOKMARK [1][-]{section.4.1}{Synthetic lethal gene candidates in breast cancer}{chapter.4}% 115
\BOOKMARK [1][-]{section.4.2}{CDH1 analysis with subgroups}{chapter.4}% 116
\BOOKMARK [1][-]{section.4.3}{Cell Line Analysis}{chapter.4}% 117
\BOOKMARK [1][-]{section.4.4}{Mutation, Copy Number, and Methylation}{chapter.4}% 118
\BOOKMARK [1][-]{section.4.5}{Mutation Analysis, Pathway Expression, and Metagene Synthetic Lethality}{chapter.4}% 119
\BOOKMARK [1][-]{section.4.6}{Pathway SL}{chapter.4}% 120
\BOOKMARK [1][-]{section.4.7}{Comparison of gene SL predictions and siRNA screen candidates}{chapter.4}% 121
\BOOKMARK [1][-]{section.4.8}{Permutation or Re-Sampling of genes for pathway enrichment.}{chapter.4}% 122
\BOOKMARK [1][-]{section.4.9}{Comparison of candidate SL Pathways}{chapter.4}% 123
\BOOKMARK [1][-]{section.4.10}{ANOVA of Expression Predictors}{chapter.4}% 124
\BOOKMARK [1][-]{section.4.11}{Global Synthetic Lethality}{chapter.4}% 125
\BOOKMARK [2][-]{subsection.4.11.1}{Hub Genes}{section.4.11}% 126
\BOOKMARK [1][-]{section.4.12}{Metagene Analysis}{chapter.4}% 127
\BOOKMARK [2][-]{subsection.4.12.1}{Pathway expression}{section.4.12}% 128
\BOOKMARK [2][-]{subsection.4.12.2}{Somatic mutation}{section.4.12}% 129
\BOOKMARK [2][-]{subsection.4.12.3}{Synthetic lethal metagenes}{section.4.12}% 130
\BOOKMARK [1][-]{section.4.13}{Replication in stomach cancer}{chapter.4}% 131
\BOOKMARK [1][-]{section.4.14}{Important Results}{chapter.4}% 132
\BOOKMARK [0][-]{chapter.5}{Synthetic Lethal Pathway Structure}{}% 133
\BOOKMARK [1][-]{section.5.1}{Reactome Network structure and Information Centrality as a measure of gene essentiality}{chapter.5}% 134
\BOOKMARK [1][-]{section.5.2}{Synthetic lethal genes in synthetic lethal pathways}{chapter.5}% 135
\BOOKMARK [1][-]{section.5.3}{Centrality and connectivity of synthetic lethal genes}{chapter.5}% 136
\BOOKMARK [1][-]{section.5.4}{Upstream or downstream synthetic lethal candidates}{chapter.5}% 137
\BOOKMARK [1][-]{section.5.5}{Hierachical approach}{chapter.5}% 138
\BOOKMARK [1][-]{section.5.6}{Discussion}{chapter.5}% 139
\BOOKMARK [1][-]{section.5.7}{Conclusion}{chapter.5}% 140
\BOOKMARK [0][-]{chapter.6}{Simulation and Modeling of Synthetic Lethal Pathways}{}% 141
\BOOKMARK [1][-]{section.6.1}{Simulations and Modelling Synthetic Lethality in Expression Data}{chapter.6}% 142
\BOOKMARK [1][-]{section.6.2}{Simulations over simple graph structures}{chapter.6}% 143
\BOOKMARK [2][-]{subsection.6.2.1}{Performance}{section.6.2}% 144
\BOOKMARK [2][-]{subsection.6.2.2}{Synthetic lethality across graph stuctures}{section.6.2}% 145
\BOOKMARK [2][-]{subsection.6.2.3}{Performance with inhibition links}{section.6.2}% 146
\BOOKMARK [2][-]{subsection.6.2.4}{Performance with 20,000 genes}{section.6.2}% 147
\BOOKMARK [1][-]{section.6.3}{Simulations over pathway-based graphs}{chapter.6}% 148
\BOOKMARK [1][-]{section.6.4}{Comparing methods}{chapter.6}% 149
\BOOKMARK [2][-]{subsection.6.4.1}{SLIPT and Chi-Squared}{section.6.4}% 150
\BOOKMARK [3][-]{subsubsection.6.4.1.1}{Correlated query genes}{subsection.6.4.1}% 151
\BOOKMARK [2][-]{subsection.6.4.2}{Correlation}{section.6.4}% 152
\BOOKMARK [2][-]{subsection.6.4.3}{Bimodality with BiSEp}{section.6.4}% 153
\BOOKMARK [0][-]{chapter.7}{Discussion}{}% 154
\BOOKMARK [1][-]{section.7.1}{Significance}{chapter.7}% 155
\BOOKMARK [1][-]{section.7.2}{Future Directions}{chapter.7}% 156
\BOOKMARK [1][-]{section.7.3}{Conclusion}{chapter.7}% 157
\BOOKMARK [0][-]{chapter.8}{Conclusion}{}% 158
\BOOKMARK [0][-]{chapter.8}{References}{}% 159
\BOOKMARK [0][-]{appendix.A}{Sample Correlation}{}% 160
\BOOKMARK [0][-]{appendix.B}{Software Used for Thesis}{}% 161
\BOOKMARK [0][-]{appendix.C}{Secondary Screen Data}{}% 162
